(Q43576719)

24 November 2017

title

[(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease (English)

1 reference

24 November 2017

1 reference

Rinne OJ

1

1 reference

24 November 2017

Nurmi E

2

1 reference

24 November 2017

Ruottinen HM

3

1 reference

24 November 2017

Bergman J

4

1 reference

24 November 2017

Eskola O

5

1 reference

24 November 2017

Solin O

6

1 reference

24 November 2017

publication date

1 June 2001

1 reference

24 November 2017

1 reference

24 November 2017

volume

40

1 reference

24 November 2017

issue

3

1 reference

24 November 2017

page(s)

193-200

1 reference

Fluorine-18-labeled fluorine gas for synthesis of tracer molecules

24 November 2017

cites work

1 reference

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

21 January 2018

1 reference

High potency cocaine analogs: neurochemical, imaging, and behavioral studies

21 January 2018

1 reference

[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease

21 January 2018

1 reference

Determination of plasma [18F]-6-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects

21 January 2018

1 reference

Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

21 January 2018

1 reference

The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.

21 January 2018

1 reference

Ageing and Parkinson's disease: substantia nigra regional selectivity

21 January 2018

1 reference

Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease.

21 January 2018

1 reference

[11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold.

21 January 2018

1 reference

[18F]CFT ([18F]WIN 35,428), a radioligand to study the dopamine transporter with PET: biodistribution in rats.

21 January 2018

1 reference

A clinicopathologic study of 100 cases of Parkinson's disease

21 January 2018

1 reference

Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease

21 January 2018

1 reference

Comparison between the decrease of dopamine transporter and that of L-DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models.

21 January 2018

1 reference

Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications

21 January 2018

1 reference

Dopamine transporter: biochemistry, pharmacology and imaging

21 January 2018

1 reference

[18F]CFT [(18F)WIN 35,428], a radioligand to study the dopamine transporter with PET: characterization in human subjects.

21 January 2018

1 reference

Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography

21 January 2018

1 reference

The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease.

21 January 2018

1 reference

[123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease.

21 January 2018

1 reference

Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study

21 January 2018

1 reference

Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra

21 January 2018

1 reference

PET examination of the monoamine transporter with [11C]beta-CIT and [11C]beta-CFT in early Parkinson's disease.

21 January 2018

1 reference

Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease

21 January 2018

1 reference

Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data.

21 January 2018

1 reference

Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease.

21 January 2018

1 reference

Monoamine re-uptake sites in the human brain evaluated in vivo by means of 11C-nomifensine and positron emission tomography: the effects of age and Parkinson's disease

21 January 2018

1 reference

The metabolic anatomy of Parkinson's disease: Complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/SYN.1042

1 reference

24 November 2017

1 reference